HDFC Securities reviews second-quarter performance for companies in both the pharma and metals sectors, with particular focus on Divi’s Laboratories and Tata Steel. The coverage comes after Q2 results, tying the broker’s update to how investors may view the latest earnings.
Both reports from NDTV frame the update around a potential upside call from HDFC Securities, with “up to 34%” mentioned in the headlines. While the two items largely mirror each other in scope—pharma and metal stocks, led by Divi’s Laboratories and Tata Steel—the second version also cues readers to check “new target prices,” indicating additional emphasis on revised valuation levels.
Overall, the differing emphasis is mainly structural: whether the story foregrounds the broker’s upside figure alone or also signals the inclusion of updated target prices. Neither summary provided details specific figures from the companies’ Q2 results or the broker’s methodology beyond the review itself.